A Review of New Fluoroquinolones

@article{Zhanel2006ARO,
  title={A Review of New Fluoroquinolones},
  author={George G. Zhanel and Sonya Fontaine and Heather J. Adam and Kristen N. Schurek and Matthew Mayer and Ayman Noreddin and Alfred S. Gin and Ethan Rubinstein and Daryl J. Hoban},
  journal={Treatments in Respiratory Medicine},
  year={2006},
  volume={5},
  pages={437-465}
}
The new respiratory fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and on the horizon, garenoxacin) offer many improved qualities over older agents such as ciprofloxacin. These include retaining excellent activity against Gram-negative bacilli, with improved Gram-positive activity (including Streptococcus pneumoniae and Staphylococcus aureus). In addition, gatifloxacin, moxifloxacin and garenoxacin all demonstrate increased anaerobic activity (including activity… 

Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.

TLDR
Levofloxacin is a valuable antimicrobial agent that has activity against a wide range of bacterial pathogens; however, its use should be considered carefully so that the potential for resistance selection can be minimized and its usefulness in severe infections and against a range of penicillin- and macrolide-resistant pathogens can be maintained.

Clinical Role of an Injectable New Quinolone Antibiotic , Pazufloxacine Mesilate

TLDR
PZFX showed clinical efficacy and safety same as injectable cephem group antibacterial drug ceftazidime (CAZ) in infection of more than medium severity and is anticipated as a choice useful for treatment of bacterial infection.

Multidrug-Resistant Streptococcus pneumoniae Infections

TLDR
The so-called respiratory fluoroquinolones offer the advantages of easy administration and a spectrum covering extracellular and intracellular pathogens, however, their broad spectrum raises questions regarding the global risk of resistance selection and their safety profile is far from optimal for wide use in the community.

New antimicrobial molecules and new antibiotic strategies.

TLDR
Few new agents have reached the market in the last decade with potential interest for community-acquired pneumonia (CAP) treatment, including linezolid (the first oxazolidinone in clinical use), new fluoroquinolones, cefditoren, ertapenem, and telithromycin.

Use of microdialysis for the assessment of fluoroquinolone pharmacokinetics in the clinical practice

Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial

TLDR
Among patients with CAP hospitalized to non-ICU wards, erythromycin use was associated with a 68% increased risk of hospital-acquired cardiac events, mainly heart failure.

A Review of Immunomodulatory Effects of Fluoroquinolones

TLDR
This study aims to review past research on the immunomodulatory effects of FQs on the expression of cytokines, especially IL-2 and to discuss controversial investigations.

References

SHOWING 1-10 OF 244 REFERENCES

A Critical Review of the Fluoroquinolones

TLDR
The new fluoroquinolones offer several advantages over ciprofloxacin and are emerging as important therapeutic agents in the treatment of community-acquired respiratory infections, and may be used orally in place of intravenous antibacterials.

Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.

  • L. SaravolatzJ. Leggett
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2003
TLDR
These agents can be useful for treatment of bacterial respiratory tract infections in patients who are allergic to beta-lactams, but caution must be exercised to avoid the potential for selection of widespread resistance, which may occur with indiscriminate use.

Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections

TLDR
Gemifloxacin is the most potent antimicrobial agent in vitro for S. pneumoniae, and has excellent activity against the other key pathogens of acute bacterial exacerbations of chronic bronchitis and community acquired pneumonia, including the atypical microorganisms.

In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds.

TLDR
The broad in vitro spectrum of gatifloxacin is promising for the treatment of mixed anaerobic infections, especially those of the respiratory tract, ear, sinus, skin and soft tissues, and bite wounds.

Gatifloxacin, an Advanced 8‐Methoxy Fluoroquinolone

Gatifloxacin is a new 8—methoxy‐fluoroquinolone antibiotic approved for use in the United States in December 1999. It has a broad spectrum of activity with potent activity against gram‐positive

The new fluoroquinolones: A critical review.

  • G. ZhanelA. Walkty D. Hoban
  • Medicine, Biology
    The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
  • 1999
TLDR
The new fluoroquinolones have the potential to emerge as important therapeutic agents in the treatment of respiratory tract and genitourinary tract infections and may result in savings in situations where they can be used orally in place of intravenous antibiotics.

Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections

TLDR
Gemifloxacin may be a suitable choice for empiric treatment of CAP or AECB, however, due to the significant history of fluoroquinolone-induced hepatic failure and dermatologic complications, the use of this drug should be closely monitored.

In Vitro Antibacterial Activity and Pharmacodynamics of New Quinolones

  • A. DalhoffF. Schmitz
  • Biology, Medicine
    European Journal of Clinical Microbiology and Infectious Diseases
  • 2003
TLDR
Drugs with the most favourable pharmacokinetic/pharmacodynamic characteristics should be used as first-line agents in order to preserve the potential of this drug class and, most importantly, to provide the patient with an optimally effective regimen.

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

TLDR
Clinical trials recruiting non-Japanese patients are in progress and these results will form a basis on which future recommendations for the broader use of levofloxacin can be made, as it has potential as a broad spectrum antibacterial drug in the treatment of a variety of infections.
...